Related Experiment Video
Updated: Apr 4, 2026
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
Published on: October 5, 2015
Equivalent CD34+ selection outcomes with CliniMACS prodigy and CliniMACS plus, enabling cryopreserved product
Anne-Line Chateau1, Clémence Demerle1, Pierre Lignee1
1Centre de Thérapie Cellulaire, Institut Paoli-Calmettes, Marseille, France; Module Biothérapies du Centre d'Investigation Clinique de Marseille, AP-HM, Aix- Marseille Université, Institut Paoli-Calmettes, CBT-1409 Inserm, Marseille, France.
The CliniMACS Prodigy fully automates CD34+ cell selection, matching CliniMACS Plus performance for fresh products and successfully processing thawed apheresis. This improves efficiency and flexibility in cell therapy manufacturing.
Area of Science:
- Cellular immunotherapy
- Hematopoietic stem cell transplantation
- Bioprocessing technology
Background:
- The CliniMACS Plus CS2 device is being discontinued, necessitating a transition to new automated systems.
- CD34+ immunoselection is crucial for graft engineering in cell therapy and ATMP manufacturing.
- Evaluating automated platforms is essential for maintaining and improving cell processing workflows.
Purpose of the Study:
- To validate the CliniMACS Prodigy for CD34+ immunoselection.
- To assess the performance of the CliniMACS Prodigy using both fresh and thawed apheresis products.
- To compare the efficiency and outcomes of the CliniMACS Prodigy against the CliniMACS Plus.
Main Methods:
- CD34+ immunoselection was performed on fresh and thawed apheresis products using CliniMACS Plus and CliniMACS Prodigy.
- Thawed products were processed after thawing, washing, and resuspension.
- Flow cytometry was used for quantifying CD34+ and CD45+ cells, and T-cell populations.
Main Results:
- CliniMACS Prodigy demonstrated comparable CD34+ purity (97%) and viability (99%) to CliniMACS Plus (95% purity, 95% viability) for fresh products.
- CD34+ recovery was higher with Prodigy (66%) versus Plus (53%), while T-cell depletion was slightly better with Plus.
- Processing thawed apheresis on Prodigy yielded 98% CD34+ purity, 51% recovery, and acceptable T-cell depletion.
- Hands-on time was significantly reduced with the automated Prodigy system (2 hours vs. 5 hours).
Conclusions:
- The CliniMACS Prodigy platform reliably performs CD34+ immunoselection from both fresh and thawed apheresis products.
- The automated workflow enhances standardization, efficiency, and flexibility in graft engineering and ATMP manufacturing.
- The ability to process thawed products expands clinical options and utilizes cryopreserved resources.
